Han et al [73] studied the effect of NAC in lung cancer patients diagnosed with post radiation pneumonitis
Patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not receive GLP-1 agonists
As the discontinuation rates were also high with the twice daily danuglipron at the phase 2 obesity trial (as discussed above), twice daily danuglirpon formulation will not advance into phase 3 studies, but an improved once-daily formulation with an aim to improve tolerability profile is currently under assessment [27]
For vendor evaluation guidance, see our best peptide vendors guide
Semaglutide may lead to common gastrointestinal side effects like vomiting, nausea, diarrhea, and constipation
Evidence Summary No robust trial data demonstrating folate depletion attributable to GLP-1 therapy alone